Catalyst Capital Advisors’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Catalyst Capital Advisors’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-70,000	Closed	-$164K	–	660
2015 Q2	$164K	Hold	70,000	–	–	0.02%	324
2015 Q1	$307K	Hold	70,000	–	–	0.04%	251
2014 Q4	$337K	Buy	+70,000	New	+$313K	0.04%	265
2014 Q1	–	Sell	-37,180	Closed	-$354K	–	374
2013 Q4	$354K	Buy	+37,180	New	+$290K	0.11%	194

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Catalyst Capital Advisors's TLOG Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2015, closing a stake of 70,000 shares — an estimated $164K sold.

Catalyst Capital Advisors first reported a position in TLOG in Q4 2013 and held it in 4 quarters. The position peaked at $354K in Q4 2013. 29 funds tracked by Wall St. Rank hold TLOG as of Q3 2015.

Catalyst Capital Advisors reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2015 after selling out during the quarter.
Catalyst Capital Advisors sold 70,000 TetraLogic Pharmaceuticals Corporation shares in Q3 2015, an estimated $164K.
Catalyst Capital Advisors first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 4 quarters.
Catalyst Capital Advisors's TetraLogic Pharmaceuticals Corporation position peaked at $354K in Q4 2013.
29 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.